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Trichloroethylene (TCE; CAS Registry no.
79-01-6) is a chlorinated solvent that has been
widely used as a metal degreaser, extractant,
and chemical intermediate and is now a com-
mon environmental contaminant. TCE has
been identified in at least 1,500 hazardous
waste sites regulated under the Comprehensive
Environmental Response, Compensation, and
Liability Act of 1980 (CERCLA 1980) or the
Resource Conservation and Recovery Act of
1976 (RCRA 1976). TCE can be released into
the atmosphere from vapor degreasing opera-
tions, enter surface waters via direct discharges,
and enter groundwater through leaching from
disposal operations and Superfund sites. In
addition, TCE can be released to indoor air
from use of consumer products, vapor intru-
sion from groundwater through underground
walls and floors, and volatilization from the
water supply [Agency for Toxic Substances
and Disease Registry (ATSDR) 1997; Hers
et al. 2001; Wu and Schaum 2001].
Toxicologically, TCE is an inherently
complex chemical in terms of metabolism,
observed effects, and mode of action (MOA),
and there is a wide spectrum of views on many
scientific issues related to TCE health risks.
Consequently, in updating its previous TCE
health risk assessments [U.S. Environmental
Protection Agency (U.S. EPA) 1985, 1987],
the U.S. EPA solicited scientiﬁc perspectives 
from many different groups and individuals.
Throughout this scientiﬁc outreach effort (e.g.,
meetings in Williamsburg, Virginia, in 1993
and 1995), the goal of the U.S. EPA was to
encourage a diversity of views and encompass a
broad range of expertise rather than seek con-
sensus. These efforts culminated in 2000 when,
under the sponsorship of the U.S. EPA, the
U.S. Air Force, the U.S. Department of Energy,
the National Institute of Environmental 
Health Sciences, and the Halogenated Solvents
Industry Alliance, Inc., 16 state-of-the-science
(SOS) papers were published as a monograph in
a supplemental issue of Environmental Health
Perspectives (Scott and Cogliano 2000). These
papers presented reviews on a range of scientiﬁc
subjects relevant to TCE health risk assessment,
including pharmacokinetics, MOA, epidemiol-
ogy, and dose–response analysis, and the U.S.
EPA drew extensively from them in developing
its 2001 draft “Trichloroethylene Health Risk
Assessment: Synthesis and Characterization”
(U.S. EPA 2001). This draft was subsequently
peer reviewed by the U.S. EPA Science Advisory
Board (U.S. EPA 2002).
Since that time, substantial new literature
has been published relevant to the characteri-
zation of TCE hazard and dose response [for a
cross-section of recently published research,
see U.S. EPA (2004)]. Some of this research is
speciﬁc to TCE or its metabolites, and some
of it describes advances in scientiﬁc ﬁelds that
are more general but that have potential rele-
vance to characterizing the human health risks
from TCE. Although some scientiﬁc conclu-
sions can be drawn from this updated body of
data, speculation as to the impact of these data
on the ﬁnal risk assessment of TCE would be
premature at this point, given the ongoing
National Academy of Sciences consultation
(NAS 2006) and the subsequently planned
revision of the U.S. EPA TCE risk assessment.
Therefore, the articles in this mini-mono-
graph build on the SOS papers published in
2000 by reviewing recently published litera-
ture framed within the context of how it
informs a number of key scientific issues
believed to be most critical in developing a
revised risk assessment. The summaries below
brieﬂy describe why these scientiﬁc areas are
critical to the hazard or dose–response charac-
terization of TCE, how they are or have been
scientifically complex or controversial, and
recently published scientific literature that
may be relevant.
Key Scientiﬁc Issues in TCE
and Human Health
Complex pharmacokinetics. As discussed in
Chiu et al. (2006), understanding TCE
pharmacokinetics—absorption, distribution,
metabolism, and elimination—is critical to
both the qualitative and the quantitative assess-
ments of human health risks from environ-
mental exposures. On a qualitative level,
pharmacokinetic information can help identify
chemical species that may be toxicologically
important, by predicting its presence in target
tissues. In addition, the delineation of inter-
and intraspecies differences can provide insights
into how laboratory animal and epidemiologic
data may inform overall human health risks
and how individuals may differ in their suscep-
tibility. Quantitatively, this information may
allow the development of physiologically based
pharmacokinetic (PBPK) models to describe
the relationship between external measures of
exposure and internal measures of toxicologi-
cally relevant dose. For TCE, understanding
metabolism is particularly important because,
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Trichloroethylene (TCE) is a common environmental contaminant at hazardous waste sites and in
ambient and indoor air. Assessing the human health risks of TCE is challenging because of its
inherently complex metabolism and toxicity and the widely varying perspectives on a number of
critical scientific issues. Because of this complexity, the U.S. Environmental Protection Agency
(EPA) drew upon scientific input and expertise from a wide range of groups and individuals in
developing its 2001 draft health risk assessment of TCE. This scientiﬁc outreach, which was aimed
at engaging a diversity of perspectives rather than developing consensus, culminated in 2000 with
16 state-of-the-science articles published together as an Environmental Health Perspectives supple-
ment. Since that time, a substantial amount of new scientiﬁc research has been published that is rel-
evant to assessing TCE health risks. Moreover, a number of difficult or controversial scientific
issues remain unresolved and are the subject of a scientiﬁc consultation with the National Academy
of Sciences coordinated by the White House Ofﬁce of Science and Technology Policy and co-spon-
sored by a number of federal agencies, including the U.S. EPA. The articles included in this mini-
monograph provide a scientiﬁc update on the most prominent of these issues: the pharmacokinetics
of TCE and its metabolites, mode(s) of action and effects of TCE metabolites, the role of peroxi-
some proliferator–activated receptor in TCE toxicity, and TCE cancer epidemiology. Key words:
epidemiology, mode of action, peroxisome proliferators, pharmacokinetics, trichloroethylene, risk
assessment. Environ Health Perspect 114:1445–1449 (2006). doi:10.1289/ehp.8690 available via
http://dx.doi.org/ [Online 9 May 2006]as discussed below, for many end points of
observed toxicity, the active agent(s) is thought
to be a metabolite(s) rather than the parent
compound.
As described in Lash et al. (2000a), TCE is
a volatile, lipophilic organic solvent that is
rapidly absorbed and readily distributed
throughout the body. TCE is metabolized
primarily by two pathways: oxidation via
cytochrome P450s and conjugation with glu-
tathione via glutathione S-transferase. There is
an extensive database of in vitro and in vivo
studies in both humans and laboratory animals
related to TCE pharmacokinetics; these data
have been used to varying degrees in the devel-
opment of PBPK models for TCE and its
metabolites. Although the general scheme of
TCE metabolism is relatively noncontroversial,
the questions of which particular metabolites
are formed—in what quantities across species
and with what toxicologic significance—are
some of the key scientiﬁc issues about which
there are differing perspectives. Chiu et al.
(2006) summarizes some of the outstanding
scientiﬁc uncertainties in TCE pharmacokinet-
ics and PBPK modeling with a focus on
insights that recent data and analyses provide
on issues of particular importance to support-
ing risk assessment. For instance, since 2001,
there have been several additional TCE-speciﬁc
PBPK modeling efforts as well as more general
methodologic advances in characterizing PBPK
model uncertainty and variability. Chiu et al.
(2006) concludes that pending the evaluation
of a number of additional structural hypothe-
ses, such as enterohepatic recirculation, plasma
binding, and ﬂow- or diffusion-limited treat-
ment of tissue distribution, rigorous applica-
tion of PBPK modeling to risk assessment
appears feasible at least for TCE and its major
oxidative metabolites, trichloroacetic acid
(TCA) and trichloroethanol. However, there
are a number of metabolites of potential toxi-
cologic interest, such as chloral, dichloroacetic
acid (DCA), or those derived from glutathione
conjugation, for which reliable data are sparse
because of analytical difﬁculties or low concen-
trations in systemic circulation. Without addi-
tional data, it will be a challenge to develop
reliable dosimetry for such cases.
TCE toxicity and MOAs. The articles by
Caldwell and Keshava (2006) and Keshava and
Caldwell (2006) are discussions of the toxicity
of TCE and its metabolites as well as key infor-
mation related to various MOA hypotheses. As
reviewed in the U.S. EPA 2001 draft TCE
health risk assessment (U.S. EPA 2001), associ-
ations have been reported between TCE and
toxicity in a number of organs and tissues.
Acute or short-term symptoms of neurotoxicity
such as drowsiness, dizziness, and headaches
are well established (in fact, TCE was once
used as an anesthetic), with a number of stud-
ies reporting similar effects with longer-term or
chronic exposure (Boyes et al. 2000). Several
cancers have been observed in rodent bioassays,
including cancers of the liver, kidney, and lung
as well as lymphomas, with some related non-
cancer effects observed as well. For these can-
cers, associations have also been reported in
epidemiologic studies (Raaschou-Nielsen et al.
2003; Wartenberg et al. 2000b). Good animal
models are lacking for other cancers observed
in epidemiologic studies. A number of effects
in other organs or systems, including the
endocrine and reproductive systems and the
developing fetus (e.g., cardiac development),
have also been reported.
For liver and kidney effects, there are a
number of hypothesized MOAs with varying
levels of support (Bull 2000; Lash et al.
2000b), whereas for other effects, there is
less—or in most cases no—information on
MOAs. For liver tumors, proposed MOAs
include peroxisome proliferation; oxidative
stress; cell-signaling resulting in alterations in
cell replication, selection, or apoptosis; and
effects on DNA (U.S. EPA 2001). For kidney
tumors, they include genotoxicity, accumula-
tion of α2µ-globulin, peroxisome proliferation,
oxidative stress, nephrotoxicity/cytotoxicity
(including the role of formic acid), and the
potential role of mutations in the von Hippel-
Lindau tumor (VHL) suppressor gene (U.S.
EPA 2001).
Part of the reason for so many hypothe-
sized MOAs for TCE toxicity is that exposure
to TCE results in a complex internal mixture
of parent compound and its metabolites, each
of which may act through different MOAs.
Thus, understanding which components of
this mixture are toxicologically important is a
critical step in characterizing the potential
human health hazard of TCE. Caldwell and
Keshava (2006) review the recent toxicity liter-
ature on TCE metabolites with a focus on
MOA studies that can particularly help inform
TCE toxicity for the liver and kidney. This
information not only aids in the identiﬁcation
of the active agent or agents of TCE toxicity
(essential for the selection of dose metrics to
be used in deriving quantitative estimates of
risk) but also provides insights into TCE’s
potential MOAs. Moreover, although phar-
macokinetic analyses provide substantial infor-
mation on the prediction of metabolites that
circulate at sufﬁcient quantities to be readily
detected, the “internal mixture” produced by
TCE exposure may contain a number of
locally generated or low-concentration
metabolites not easily quantiﬁed in pharmaco-
kinetic studies but may nonetheless be toxico-
logically important.
Although much of the attention on liver
MOAs has focused on the role of peroxisome
proliferator–activated receptor α (PPARα)
[discussed in Keshava and Caldwell (2006)],
Caldwell and Keshava (2006) discuss a number
of other hypotheses for which there is recently
published information, such as DNA hypo-
methylation. This is important because even if
PPARα agonism were to present a plausible
MOA, an overriding requirement for reliance
on that MOA as a sole indicator of human risk
would be that other MOAs have been
excluded. This point regarding consideration
of alternative hypotheses was emphasized by a
recent Federal Insecticide, Fungicide, and
Rodenticide Act Scientific Advisory Panel
review relating to PPARα (FIFRA SAP 2004)
and is a key part of the U.S. EPA cancer guide-
lines (U.S. EPA 2005).
As mentioned previously, much of the
attention on MOA hypotheses for TCE toxic-
ity has focused on the role of PPARα, the sub-
ject of the article by Keshava and Caldwell
(2006). Although there has been only limited
research on PPARα and TCE speciﬁcally, a vast
literature has emerged on PPARs more gener-
ally in the last 4 or 5 years [a search of the
PubMed database (http://www.ncbi.nlm.nih.
gov/entrez/query.fcgi) on 20 September 2005
for “peroxisome proliferator-activated receptor”
returned 3,495 entries published since 2001].
Given this new information, particularly with
respect to the pleiotropic nature of PPARα-
related effects, Keshava and Caldwell (2006)
discuss various recent hypotheses about the
MOA or MOAs for PPAR agonist–related
tumorigenesis.
The issue of whether PPARα agonists
pose human health risks is controversial, both
in the case of TCE and in general. TCE and
two of its key metabolites, TCA and DCA,
have been characterized as weak peroxisome
proliferators. In the last 10 years, there has
been a considerable evolution in the hypothe-
ses about the relationship between PPARα
agonism and tumor induction in rodents.
Initially, it was hypothesized that the prolifer-
ation of peroxisomes themselves was causally
related to cancer (e.g., Cattley et al. 1998),
but today most investigators believe the frank
effect is, at best, associative (Klaunig et al.
2003; Melnick 2001). Part of the controversy,
therefore, stems from a matter of interpreta-
tion, particularly the degree to which infer-
ences should be made about human risk on
the basis of such an association.
Another point of controversy stems from
the question of how sensitive are humans to
events causally related to carcinogenesis. It is
clear now that PPARα can be activated in
humans and that humans are at least as sensi-
tive as laboratory animals for some effects, that
is, those related to lipid regulation and that are
the target of an extensive effort to develop
pharmaceuticals using this mechanism.
Characterizing the effects from PPARα ago-
nism in the identification of key events that
may constitute a cogent MOA hypothesis 
for tumor induction has yet to be resolved.
Chiu et al.
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adequacy of human data to determine the
carcinogenic potential in humans for drugs
that cause peroxisome proliferation in rodents
(FIFRA SAP 2004; Melnick 2001; Newman
and Hulley 1996). For all these issues, an
examination of the full spectrum of pleiotropic
responses to PPARα agonism—particularly
extraperoxisomal effects and their relationships
with PPARα-independent processes—is
needed. Keshava and Caldwell (2006) review
this spectrum of effects with a focus on
recently published data.
Epidemiologic studies. The ﬁnal article by
Scott and Chiu (2006) discusses TCE cancer
Issues in trichloroethylene risk assessment
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Appendix: Charge to the National Academy of Sciences Committee on Assessing the Human
Health Risks of Trichloroethylene: Key Scientiﬁc Issues.a
The NAS panel of experts shall use their best scientiﬁc judgment to
provide advice on critical underlying speciﬁc scientiﬁc issues related
to the assessment of the potential human health risks from environ-
mental exposure to TCE. The panel shall strive to reach a consensus
on all critical issues.
In providing its advice and review, the NAS panel shall highlight
issues critical to the development of an objective, realistic, and scien-
tiﬁcally balanced TCE health risk assessment. In doing so, the panel
should distinguish between issues that can be addressed through
short-term analyses and issues that are more appropriately addressed
through medium- or long-term research projects. Special attention
should be given to the availability of appropriate data and methods to
implement the panel’s advice, as well as the distinction between data
analysis and data generation.
The following outlines the scientiﬁc issues upon which to focus
the evaluation:
Hazard Characterization/Mode of Action
Key scientiﬁc issues regarding various alternative hypotheses as to the
MOAs for TCE toxicity and their relevance to humans include the
following:
• Liver tumors: Production and toxicological importance of metabo-
lites TCA and DCA in rodents and humans; strength of evidence
for various hypothesized MOAs, including peroxisome prolifera-
tion; cell signaling resulting in alterations in cell replication, selec-
tion, and/or apoptosis; and effects on DNA.
• Kidney tumors: Production and toxicologic importance of various
glutathione S-transferase–pathway metabolites such as DCVG
[S-(1,2-dichlorovinyl)glutathione] and DCVC [S-(1,2-dichloro-
vinyl)-L-cysteine] in rats and humans; strength of evidence for vari-
ous hypothesized MOAs, including genotoxicity; accumulation of
α2µ-globulin; peroxisome proliferation; nephrotoxicity/cytotoxicity
(including role of formic acid).
• Strength of evidence for various hypothesized mode(s) of action for
other effects (e.g., neurotoxicity; noncancer liver and kidney toxicity;
immunotoxicity and lymphoid cancer; developmental, reproductive,
and endocrine effects; pulmonary effects and lung cancer).
• Identiﬁcation of key events in modes of action.
• Potential for contributions from multiple modes of action.
• Dose-dependent differences in MOAs.
Key scientiﬁc issues regarding possible approaches to synthesize epi-
demiologic data in informing the hazard characterization of TCE
include the following:
• Use of meta-analytical techniques to summarize epidemiologic ﬁnd-
ings, including methods for classifying and weighting studies.
• Strengths and limitations of the body of epidemiologic evidence with
respect to kidney cancer.
• Strength of evidence provided by reported molecular information on
associations with mutations in the von Hippel-Landau tumor
suppressor gene.
• Identification of key epidemiologic studies for informing overall
conclusions on TCE potential carcinogenicity.
Key scientiﬁc issues regarding the potential for differential susceptibil-
ity to TCE’s toxic effects in different subpopulations or life stages
include the following:
• Effects of altered metabolism, whether by intrinsic or acquired fac-
tors, and/or cumulative exposures on the toxicologically important
internal doses of TCE and its metabolites.
• Pharmacodynamic factors such as genetic polymorphism, disease
states, and developmental windows as they relate to TCE toxicity.
• Degree to which differential susceptibility can be quantiﬁed.
Physiologically Based Pharmacokinetic Modeling
Key scientiﬁc issues regarding approaches for pharmacokinetic modeling
based on existing metabolic information of TCE include the following:
• Relative strengths and limitations of different model structures and
parameterizations, including the tradeoff between model complexity
(and hence completeness) and uncertainty.
• Evaluation of model uncertainties, including the use of Markov-
Chain Monte Carlo methods.
Key scientiﬁc issues regarding the uses of pharmacokinetic modeling
results for risk assessment of TCE include the following:
•Dose metrics [e.g., TCA AUC (area under the curve), DCA AUC in
blood and/or tissues] for developing human equivalent doses, route-
to-route extrapolations, or use in biologically based dose–response
modeling.
• Addressing uncertainties associated with PBPK-based dose-metrics,
including the consideration of non-PBPK-based scaling approaches.
• Assessment of the impact of human variation and other factors such
as enzyme induction or chemical mixtures on toxicologically impor-
tant doses.
Dose–Response Assessment
Key scientific issues regarding the quantitative assessment of non-
cancer risks include the following:
• Strengths and limitations of studies to consider in quantifying non-
cancer risks, including consideration of studies in various species
(including humans), of various durations (acute, short term, chronic),
and with various observed end points (e.g., liver weight changes, car-
diac anomalies in prenatal development, renal effects, endocrine
effects, and reproductive effects).
• Approaches to develop point(s) of departure, including use of PBPK-
based human equivalent doses and benchmark dose or other modeling.
• Use of PBPK-based Monte Carlo analysis quantify human variation.
Key scientiﬁc issues regarding the quantitative assessment of cancer
risks include the following:
• Strengths and limitations of studies—including both rodent studies
and epidemiologic studies—to consider in quantifying cancer risks,
including consideration the uncertainty in exposure estimates,
MOA, and species extrapolation.
• Quantitative approaches to use in estimating risk, including PBPK-
based dose estimates, linear and nonlinear extrapolation, and biologi-
cally based dose–response modeling.
• Methods to characterize the uncertainty and/or variability in estimates
of cancer risk, including consideration of both statistical (possibly
Bayesian) and nonstatistical approaches and of the potential for differ-
ential susceptibility among certain subpopulations. aFrom the U.S. Department of Energy (2004).epidemiology. Because epidemiology is based
on human data, it is a key element to the haz-
ard characterization of TCE health risks.
Epidemiologic evidence on occupational and
residential exposures can contribute informa-
tion regarding associations between exposure
and cancer. Well-conducted epidemiologic
studies that show a positive association
between an agent and a disease are accepted as
the most convincing evidence about human
risk (National Research Council 1983).
More than 80 epidemiologic studies and
reports have assessed possible associations
between TCE exposure and various health out-
comes. Many of these studies have examined
cancer mortality; fewer have examined cancer
incidence. Wartenberg et al. (2000b), as part of
the SOS papers, developed a “joint analysis” of
the cancer epidemiology studies. Cohort studies
were grouped according to the speciﬁcity of the
exposure assessment and the study results were
combined by weighting by the inverse variance,
whereas case–control and community studies
were systematically reviewed. Wartenberg et al.
(2000b) concluded that the epidemiologic evi-
dence supported an association between TCE
exposure and liver cancer, kidney cancer, and
lymphomas. Somatic mutations of the VHL
tumor suppressor gene have been found in kid-
ney tumors of TCE-exposed workers (Brauch
et al. 1999; Brüning et al. 1997). Furthermore,
these ﬁndings may inform weight of evidence
evaluations of the epidemiologic observations.
The Wartenberg et al. (2000b) analysis
was not without controversy, as it was the sub-
ject of a number of letters to the editor (e.g.,
Borak et al. 2000; Wartenberg et al. 2000a)
and several public comments on the U.S. EPA
draft assessment. Many of the comments
focused on how the studies were grouped or
how the study results were combined. In addi-
tion, alternative meta-analyses and interpreta-
tions of the epidemiologic evidence have been
published or presented since 2000 (e.g.,
Mandel and Kelsh 2001).
Cancers of the liver, kidney, and lym-
phatic system are of low incidence [≤ 2% life-
time risk of diagnosis, Ries et al. (2005)] and
are nonspecific to TCE, which partly con-
tributes to the inconsistent observations in the
body of epidemiologic evidence. Other factors
have been identiﬁed or suggested as associated
with these cancers, limiting the statistical
power of individual studies. Additionally,
mean exposure concentrations in TCE cohort
studies are relatively low, with an impact of
further limiting statistical power. Lower expo-
sure levels are not likely to produce a large
magnitude of risk. The epidemiologic picture
for TCE differs greatly from that for the
known human carcinogen vinyl chloride, for
example, where angiosarcoma is speciﬁc to this
exposure and exposure concentrations in the
epidemiologic studies are much higher than
the concentrations reported for the TCE
cohorts (Kielhorn et al. 2000).
In this light, an interpretation of the data-
base of cancer epidemiology needs to take into
consideration a number of aspects, the subject
of the article by Scott and Chiu (2006). They
ﬁrst provide an update on the epidemiologic
studies that have been published since the
Wartenberg et al. (2000b) review, including a
recent study assessing mutations in the VHL
tumor suppressor gene. Although recently pub-
lished studies appear to provide further support
for the kidney, liver, and lymphatic systems as
targets of TCE cancer toxicity, Scott and Chiu
note that a number of challenging issues need
to considered before drawing causal conclusions
as to TCE exposure and cancer.
Some of the important factors discussed by
Scott and Chiu (2006) include weighing the
strengths and limitations of various study
types, and characteristics include study differ-
ences in exposure characterization and the rela-
tive sensitivity of mortality versus incidence
data. Such differences may contribute to false-
positive or false-negative observations and need
to be factored into any overall characterization.
In addition, issues surrounding lymphomas
warrant further discussion. More recent epi-
demiologic studies of TCE exposure observe
associations with lymphoma, particularly
non-Hodgkin lymphoma (NHL) (Hansen
et al. 2001; Raaschou-Nielsen et al. 2003;
Wartenberg and Scott 2002). Evaluating asso-
ciations with malignant lymphomas poses par-
ticular challenges because they include a
diverse group of diseases such as NHL,
Hodgkin disease, multiple myeloma, and
leukemia. NHL incidence has been increasing
and is now the sixth leading cause of cancer
deaths in males in the United States (Fisher
2003). The classification of lymphoid neo-
plasms, specifically lymphomas, has recently
undergone a substantial revision, primarily on
the basis of new findings from molecular
biology, genetics, and immunology (Herrinton
1998). For this reason, Scott and Chiu (2006)
note that inconsistent observations in the epi-
demiologic studies for different categories of
lymphoid tumors may not be inconsistent
with emerging data on their pathogenesis.
Moreover, a better mechanistic understanding
of this disease may help clarify how these
tumors are associated with TCE exposure.
Next Steps in TCE Risk
Assessment
This mini-monograph does not and could not
address all the issues related to the potential
health effects of environmental exposure to
TCE that need to be addressed as the U.S.
EPA revises its assessment, but we believe it
does provide updated perspectives on some of
the more critical and contentious scientific
issues. More generally, given the complexity,
uncertainty, and varying perspectives on these
and other important scientiﬁc issues, a federal
interagency working group coordinated by 
the White House Office of Science and
Technology Policy (OSTP) decided that a sci-
entiﬁc consultation with an NAS panel would
be beneficial and informative to clarify the
SOS as the U.S. EPA moves forward in com-
pleting its health risk assessment. This consul-
tation was initiated in September 2004,
coordinated by the OSTP and co-sponsored by
a number of other federal agencies, including
the U.S. EPA, the U.S. Department of
Defense, the U.S. Department of Energy, and
the National Aeronautics and Space
Administration. The charge to the NAS is pro-
vided in the Appendix, and additional infor-
mation on this consultation is available from
the NAS website (NAS 2006). A report from
the NAS is expected in 2006.
The advice from the NAS on these and
other scientiﬁc issues, together with comments
already received from the Science Advisory
Board and the public and recently published
scientiﬁc literature, will be incorporated into a
revised U.S. EPA risk assessment of TCE.
Because of the substantial amount of new infor-
mation and analysis that is expected, the revised
draft of the assessment will undergo further
peer review and public comment before com-
pletion. We believe that through this process,
the U.S. EPA risk assessment will reflect the
SOS on the human health effects of TCE.
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